Exploring the Value of Total/Near Total Skin Clearance in Patients With a History of Moderate-Severe Psoriasis: A Real-World Survey
Author(s)
Aaron Keal, MSc1, Bruno Kranz, MSc1, Emily J. Goddard, Other1, James Hetherington, BSc1, Oluwakayode Adejoro, MD2;
1Adelphi Real World, Bollington, United Kingdom, 2Johnson & Johnson, Horsham, PA, USA
1Adelphi Real World, Bollington, United Kingdom, 2Johnson & Johnson, Horsham, PA, USA
Presentation Documents
OBJECTIVES: To compare characteristics of patients with a history of moderate-severe psoriasis (PsO) who achieved complete/near-complete skin clearance versus those who did not, and describe the value of achieving complete/near-complete skin clearance in PsO.
METHODS: Data were drawn from the Adelphi Real World PsO Disease Specific Programme™, a cross-sectional survey of dermatologists and their consulting PsO patients in the United States from December 2021-March 2022. Dermatologists reported patient characteristics including body surface area (BSA). Patients reported quality of life via the EQ-5D Visual Analogue Scale (VAS), Dermatology Life Quality Index (DLQI) and Work Productivity and Activity Impairment Questionnaires. Selected patients had history of moderate-severe PsO (BSA>3% at any point post-diagnosis). Patients were stratified by physician global assessment (PGA) at time of survey; achieved complete/near-complete skin clearance (PGA≤1) vs. didn’t achieve skin clearance (PGA>1), p<0.05 indicates significant difference.
RESULTS: Overall, 501 patients with PsO were selected for analysis; n=177 (35%) with PGA≤1 and n=324 (65%) with PGA>1. Mean ± standard deviation age for patients with PGA≤1 was 45.1±15.9 years, 52.0% were female, 78.0% were White and mean time since diagnosis was 4.5±6.4 years. For patients with PGA>1 this was 42.6±14.9 years, 50.3%, 79.6%, and 3.6±4.2 years, respectively. Patients with PGA≤1 had significantly lower PASI scores (0.4 vs. 4.9, p<0.001) and lower BSA (1.5% vs. 11.1%, p<0.001) compared to patients with PGA>1. Patients with PGA≤1 less commonly experienced scaling/flaking (32.6% vs. 62.7%), red inflamed skin (21.1% vs. 65.4%), itching (20.6% vs. 59.3%), and cracked skin (3.4% vs. 29.3%, all p<0.001). Patients with PGA≤1 had a higher mean VAS score (89.1 vs. 79.7), lower mean DLQI score (1.5 vs. 4.5), and less mean overall work impairment (5.4% vs. 13.5%, all p<0.001).
CONCLUSIONS: PsO patients who achieved complete/near-complete skin clearance experienced lower disease burden, fewer PsO symptoms, and better quality of life than those who did not.
METHODS: Data were drawn from the Adelphi Real World PsO Disease Specific Programme™, a cross-sectional survey of dermatologists and their consulting PsO patients in the United States from December 2021-March 2022. Dermatologists reported patient characteristics including body surface area (BSA). Patients reported quality of life via the EQ-5D Visual Analogue Scale (VAS), Dermatology Life Quality Index (DLQI) and Work Productivity and Activity Impairment Questionnaires. Selected patients had history of moderate-severe PsO (BSA>3% at any point post-diagnosis). Patients were stratified by physician global assessment (PGA) at time of survey; achieved complete/near-complete skin clearance (PGA≤1) vs. didn’t achieve skin clearance (PGA>1), p<0.05 indicates significant difference.
RESULTS: Overall, 501 patients with PsO were selected for analysis; n=177 (35%) with PGA≤1 and n=324 (65%) with PGA>1. Mean ± standard deviation age for patients with PGA≤1 was 45.1±15.9 years, 52.0% were female, 78.0% were White and mean time since diagnosis was 4.5±6.4 years. For patients with PGA>1 this was 42.6±14.9 years, 50.3%, 79.6%, and 3.6±4.2 years, respectively. Patients with PGA≤1 had significantly lower PASI scores (0.4 vs. 4.9, p<0.001) and lower BSA (1.5% vs. 11.1%, p<0.001) compared to patients with PGA>1. Patients with PGA≤1 less commonly experienced scaling/flaking (32.6% vs. 62.7%), red inflamed skin (21.1% vs. 65.4%), itching (20.6% vs. 59.3%), and cracked skin (3.4% vs. 29.3%, all p<0.001). Patients with PGA≤1 had a higher mean VAS score (89.1 vs. 79.7), lower mean DLQI score (1.5 vs. 4.5), and less mean overall work impairment (5.4% vs. 13.5%, all p<0.001).
CONCLUSIONS: PsO patients who achieved complete/near-complete skin clearance experienced lower disease burden, fewer PsO symptoms, and better quality of life than those who did not.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
CO192
Topic
Clinical Outcomes
Topic Subcategory
Clinical Outcomes Assessment, Clinician Reported Outcomes
Disease
SDC: Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)